ACETO Subsidiary, Rising Pharmaceuticals, to Launch Timolol Maleate Ophthalmic Solution and Ofloxacin Ophthalmic Solution

ACETO Corporation (Nasdaq:ACET), a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, announced that Rising Pharmaceuticals, Inc., its finished dosage form generics subsidiary, is launching the 0.25% and 0.5% strengths of Timolol Maleate Ophthalmic Solution, an FDA approved generic version of Merck & Co., Inc.'s Timoptic®, and the 0.3% strength of Ofloxacin Ophthalmic Solution, an FDA approved generic version of Allergan Inc.'s Ocuflox®. With these product launches, Rising is expanding its portfolio of ophthalmic products. 

According to IMS Health data, U.S. market sales for Timolol Maleate Ophthalmic Solution, which is used for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma, were approximately $60 million for the twelve months ended February 28, 2015. U.S. market sales for Ofloxacin Ophthalmic Solution, which is used for the treatment of infections caused by susceptible strains of bacteria, were approximately $20 million for the twelve months ended February 28, 2015.